FDA Expands Approval for Teplizumab to Treat Newly Diagnosed Children and Adolescents with Type 1 Diabetes
The U.S. Food and Drug Administration (FDA) has expanded its approval of teplizumab, an immunotherapy drug, to include children and adolescents aged 8 to 17 who have been newly diagnosed with Stage 3 Type 1 diabetes. This expanded approval, granted in June 2026 under the FDA's accelerated approval pathway, allows for treatment that targets the underlying autoimmune disease rather than solely managing blood sugar levels with insulin. Teplizumab works by slowing the immune system's destruction of the body's remaining insulin-producing beta cells in the pancreas. Previously, the drug was approved to delay the onset of Stage 3 Type 1 diabetes in individuals aged 1 and older with Stage 2 Type 1 diabetes. A national group of clinical trial investigators and pediatric diabetes specialists, led by Kimber Simmons, M.D., M.S., from the Barbara Davis Center for Diabetes at the University of Colorado Anschutz, has published practical guidance to assist care teams and families in navigating this new treatment option. T...
